The other day, an interesting job opening popped up in my LinkedIn feed. Pharmaceutical giant Takeda is looking for none other than a Vice President, Head of Oral Drug Products. The salary range in Boston goes up to $407,000 per year, not including bonuses. Requirements include 15-25 years of experience, profound expertise in pharmaceuticals, chemistry, engineering, and, of course, the ability to manage a global behemoth.
Well, a solid position for a solid professional. But, reading through this multi-page tome of requirements, I couldn’t shake one thought. Aren’t they trying to hire a very expensive, experienced, yet still analog processor to solve a problem that is already crying out for digitalization?
**Briefly about the company**
Takeda is not a garage startup. It’s one of the oldest and largest pharmaceutical companies in the world, with Japanese roots and a 240-year history. Their business is the development and market launch of medicines. This process is unimaginably complex, lengthy, expensive, and regulated down to the last milligram. Every tablet is the result of years of research, billion-dollar investments, and thousands of pages of documentation for regulators worldwide.
**What Pain Are They Trying to Solve?**
Let’s imagine a dialogue in a Takeda meeting room.
– We need a one-man band. He must see the entire chain: from the idea of a new molecule to a tablet in the pharmacy. He must know how to mix powders so they don’t explode at the factory in Austria, how this mixture will behave in a patient’s body in the USA, and how to describe all of this in documents for the regulator in Japan.
– So, he needs to keep data from R&D, manufacturing, clinical trials, quality assurance, and the legal department in his head? And make strategic decisions based on that?
– Exactly! Plus, manage a team of hundreds of people worldwide. His experience and intuition should shorten our development cycles and reduce risks. We need a strategist with encyclopedic knowledge.
Takeda’s problem is **managing colossal complexity**. They are looking for a person whose brain, over 25 years of work, has transformed into a unique database and decision-making model in drug development. He is a living hub, connecting disparate departments and information flows. But the human brain, even the most brilliant, has its limits.
**Now Let’s Imagine an AI-Powered Solution**
Instead of looking for one human-supercomputer, we could build the supercomputer itself. Let’s tentatively call it an “AI-driven Drug Development Platform” or, if you prefer, a “Digital Vice President.”
This system won’t replace all scientists and managers. It will replace the very “central processor” function that the hired Vice President is expected to perform. It will become a single source of truth and predictive analytics for the entire oral drug product development chain.
**How It Could Work: Approaches and Tools**
This is not science fiction, but a perfectly feasible engineering project. Here are its main steps:
1. **Creation of a Unified Knowledge Graph.** The first step is to gather all of Takeda’s disparate data into a single structure. Data on chemical compounds, laboratory test results, manufacturing process parameters (granulation, compression, coating), stability data, clinical trial results, regulatory requirements from different countries – all of this is linked into a single model. Instead of hundreds of Excel spreadsheets and PDF reports, we get a living, interconnected map of all company knowledge.
2. **Building Predictive Models.** Based on this knowledge graph, specialized AI models are trained:
* **Formulation Prediction Model:** The target product profile (e.g., “sustained-release tablet for children”) is fed into the system, and the model suggests several optimal formulations (composition of excipients, their proportions), predicting their stability and bioavailability. This solves the problem of “*oral drug product design and development*.”
* **Digital Twins of Processes:** Virtual copies of production lines are created. Before launching a real process, engineers can use a simulator to check how changes in press pressure or granulate moisture will affect tablet quality. This addresses the pain points of “*process development and scale-up*” and “*tech transfer*.”
* **Regulatory Documentation Generator (Generative AI for CMC):** Based on all data from the knowledge graph, AI can automatically generate up to 80% of the text for regulatory documents (CMC sections for IND/NDA/MAA). The system itself will pull up the necessary figures, graphs, and references, ensuring unprecedented speed and accuracy.
3. **Implementation and Reducing Distrust.** Of course, the board of directors won’t entrust drug development to a “black box.” Implementation should be phased:
* **Pilot Project:** First, the system is trained on data from an already completed successful project. Its task is to “rediscover” an already created drug. If its conclusions match the results obtained by a human team over 5 years, this is the first step towards trust.
* **AI as an Advisor:** In the next phase, AI operates in “co-pilot” mode. It suggests options, analyzes risks, but the final decision is made by a human. It doesn’t replace the expert but gives them superpowers – the ability to see all data and predict the consequences of any decision.
* **Integration into Processes:** Gradually, functions where AI proves its effectiveness (e.g., generating routine reports) are fully transferred to it, freeing up people’s time for more creative and strategic tasks.
**How to Validate AI’s Work?**
In pharmaceuticals, everything hinges on validation. How can we ensure that AI isn’t “hallucinating”?
* **Retrospective Validation:** As mentioned, we run the AI on dozens of past projects (both successful and failed). It should predict the actual outcomes with high accuracy.
* **Expert Review (Human-in-the-Loop):** No key decision generated by AI (e.g., the final formulation for clinical trials) is adopted without verification by a leading specialist. AI is a powerful tool in the hands of an expert, not a replacement for them.
* **Physical Experimentation:** The ultimate judge is reality. AI predicted that a certain formulation would be stable? We go to the lab and test it in practice. The value of AI is not to eliminate experiments, but to reduce their number from hundreds to a few, weeding out unpromising options already at the simulation stage.
Ultimately, Takeda is looking for a person who will perform the role of a highly complex information processing system. But today, creating such systems is a direct task for IT. Perhaps in 5 years, the “Head of Oral Drug Products” vacancy will require not 25 years of experience in chemistry, but the ability to set the right tasks for an AI platform and interpret its results. And that will be a completely different story.
Источник: https://www.linkedin.com/jobs/view/4403065360/
